Pfizer Stock News

By Francesco Guarascio BRUSSELS (Reuters) - Pfizer and BioNtech are set to displace AstraZeneca as the main suppliers of COVID-19 vaccines to the global COVAX programme at the start of 2022, a shift that shows the increasing importance of their shot for poorer states. The expected change comes with headaches for receiving countries that lack sufficient cold stora

Click to expand Image Companies with sterile injectable pharmaceutical manufacturing facilities that have been certified for Good Manufacturing Practices (GMP) by the European Medicines Agency and/or the US Food and Drug Administration and/or the World Health Organization. Source: https://accessibsa.org/mrna, December 2021. © 2021 Human Rights Watch (Washington, DC) The new Covid-19 variant underscores the dangers of severely unequal access to Covid-19 vaccines and the concentration of production in the US and Europe, Human Rights Watch said today. Human Rights Watch and other groups wrote to the US and German governments urging them to act on a new list published today by experts identifying more than 100 companies in Africa, Asia, and Latin America with the potential to produce mRNA vaccines. This new list makes it clear that increased production of mRNA vaccines is possible outside the US and Europe. It illustrates that the companies that developed safe and effective Covid-19 mRNA vaccines are not sharing their knowledge and technology widely with capable manufacturers.

Related Stocks: PII , WU , BA , INTC , AZPN , KLAC , MCHP , LRCX , CHRW , CPB , EFX , NOW , CERN , PFE , GD , ADBE , BLK , NOC , YUM ,

The World Health Organization Tuesday warned Omicron was spreading at an unprecedented rate and urged countries to act as drug maker Pfizer said its coronavirus pill was effective against the variant.

This time last year, ICUs were filling up with a post-Thanksgiving surge of COVID-19 patients. On December 14, 2020, the first doses of Pfizer''s COVID-19 vaccine went into arms to tears and applause.

Related Stocks: PFE , ROKU , PLUG , ZM , MRNA , APPS , BB , AMC , LMT , A , ABNB , AI , BIIB , NKLA , DAL , CMG , FSLY , DISCA ,

Microbiologist Samuel Philips sequences COVID-19 samples for variants at the Utah Public Health Laboratory in Taylorsville on Monday, Nov. 29, 2021. | Scott G Winterton, Deseret News Just how bad will COVID-19 get in Utah this winter? Well, case counts may finally be headed in the right direction but the virus new variant, omicron , is only getting started spreading across the United States. If there wasnt omicron lurking, Id be really optimistic, Dr. Eddie Stenehjem, an Intermountain Healthcare infectious diseases physician, told the Deseret News. Our numbers are going down at the same time were headed into the winter. Even better, Stenehjem said, theres hope that the new variant wont become dominant in the United States until after the holidays in January, a calculation based on omicron cases doubling in other countries every few days. Still, he said Utahns shouldnt lose sight of the damage COVID-19 continues to do in the state, keeping hospital intensive care units filled to capacity and forcing many surgeries to be delayed. Thats pretty disheartening for a lot of us, the doctor said. We hope we see a break here for at least a few weeks. Nearly all of the nations COVID-19 cases are still the delta variant that first surfaced last spring and sparked surges starting in the summer, including a recent spike that saw Utah and the Intermountain West branded the nations hot spot for the virus.

Early data, but important.

OMICRON admissions are a third lower than in South Africas first Covid wave, boosting hopes it is milder. The first real-world study of 200,000 cases there found just two doses of the Pfizer vaccine slash hospital risk by 70 per cent. And the overall chances of hospitalisation are down by 29 per cent compared to []

Heavily-Vaccinated Northeastern States Struggle With Surging Hospitalizations Fortunately, Pfizer is just about ready to roll out its new COVID pill, because case numbers are rising rapidly in the northeastern US, a part of the country that was previously overlooked because of high vaccination rates and relatively low COVID numbers. But now, emergency rooms across the region, which includes much of the Empire State, as well as the six states that comprise New England, are overflowing, while infection rates soar. CDC data clearly shows the spike in hospitalizations. Source: CDC, Bloomberg Admissions involving patients with COVID climbed 14.4% across the US in the week ended Dec. 9, according to the US Department of Health and Human Services. In New England, the rate was more than double - 33.5%. This latest surge is happening in what is perhaps the most vaccinated area of the US. In Massachusetts, where 88% of the population has had at least one dose of the vaccine, the state is planning to send out more than 2MM rapid antigen tests to the poorest communities, according to Gov.

Ballentine Partners LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 101,346 shares of the biopharmaceutical companys stock after selling 1,348 shares during the period. Ballentine Partners LLCs holdings in Pfizer were worth $4,359,000 as of its most recent SEC filing. A number []

United States President Joe Biden stated on Tuesday that he is "encouraged by the promising data released by Pfizer today" on the effectiveness of its pill against coronavirus-linked deaths …

Pfizer''s antiviral COVID-19 pill shows almost 90 per cent efficacy in preventing hospitalisations and deaths in high-risk patients, the US drug maker says.

Researchers from the Universities of Edinburgh and Oxford found there were no cases myocarditis per million second doses of either Pfizer or AstraZeneca''s Covid vaccines.